| Unknown | Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breas Locally Advanced Non-resectable Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2012-05-01 |
| Unknown | Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer Gastric Carcinoma | Phase 2 | 2012-04-01 |
| Unknown | Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer Gastric Carcinoma | Phase 1 / Phase 2 | 2011-05-01 |
| Unknown | Study of Tesetaxel in Japanese Patients With Solid Tumors Advanced Solid Tumors | Phase 1 | 2011-04-01 |
| Unknown | A Study of Tesetaxel Plus Capecitabine in Patients With Solid Tumors Solid Tumor | Phase 1 | 2011-03-01 |
| Unknown | Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer Prostate Cancer | Phase 2 | 2011-02-01 |
| Unknown | Tesetaxel as First-line Therapy for Metastatic Breast Cancer Breast Neoplasm | Phase 2 | 2010-11-01 |
| Unknown | Tesetaxel for Previously Treated Patients With Bladder Cancer Carcinoma, Transitional Cell | Phase 2 | 2010-09-01 |
| Completed | Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules Solid Tumors | Phase 1 | 2010-06-01 |
| Unknown | Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction | Phase 2 | 2010-03-01 |
| Unknown | Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH Melanoma | Phase 2 | 2010-02-01 |
| Completed | Trial of Dacarbazine With or Without Genasense in Advanced Melanoma Melanoma | Phase 3 | 2007-07-01 |
| Completed | Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors Solid Tumors | Phase 1 | 2007-05-01 |
| Unknown | Abraxane and Temodar Plus Genasense in Advanced Melanoma Melanoma | Phase 1 | 2006-11-01 |
| Withdrawn | This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/ Lymphocytic Leukemia | Phase 3 | 2006-06-01 |
| Completed | Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Normal Renal Function, Mildly Impaired Renal Function, Moderately Impaired Renal Function | Phase 1 | 2006-05-01 |
| Completed | A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine Advanced Melanoma | Phase 1 | 2006-04-01 |
| Completed | A Phase I Study of G3139 Subcutaneous in Solid Tumors Tumors | Phase 1 | 2005-12-01 |
| Terminated | Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Advanced Melanoma and Normal or Impaired, Hepatic Function | Phase 2 / Phase 3 | 2005-08-01 |
| Completed | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2003-11-01 |
| Completed | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma Non-Hodgkin's Lymphoma, Relapsed Lymphoma, Refractory Lymphoma | Phase 2 | 2002-06-01 |
| Unknown | Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer Lung Cancer | Phase 2 / Phase 3 | 2001-10-01 |
| Completed | Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory C Leukemia | Phase 3 | 2001-07-01 |
| Completed | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | 2001-01-01 |
| Completed | Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia Leukemia | Phase 2 | 2000-12-01 |
| Completed | Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Multiple Myeloma and Plasma Cell Neoplasm | Phase 3 | 2000-12-01 |
| Completed | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma Melanoma (Skin) | Phase 3 | 2000-07-01 |